Fecal Microbiota Transplantation: When Our Gut Bacteria Become a Treatment

What if certain intestinal diseases could be treated by transferring bacteria from a healthy person to a sick one? Surprising as it may sound, this idea is now a medical reality. Fecal microbiota transplantation has proven effective against certain recurrent intestinal infections and is attracting growing interest in therapeutic research.
A transplant unlike any other
We are familiar with organ, bone marrow and skin transplants. But did you know it is also possible to transplant a gut microbiota?
Known as fecal microbiota transplantation (FMT), this technique involves transferring a preparation made from a healthy donor's stool into a patient's digestive tract.
The goal is not to transfer stool as such, but to reintroduce a community of microorganisms capable of restoring certain functions of a severely disrupted gut microbiota.
Our gut is home to a complex ecosystem made up of thousands of microbial species and strains: bacteria, viruses, fungi and other microorganisms. Together, they take part in many essential functions, including digestion, the metabolism of certain nutrients, immune system function and protection against pathogens.
When this balance is severely disrupted, especially after certain antibiotic treatments, the protective functions of the microbiota can be impaired. Fecal microbiota transplantation is based precisely on this principle.
How does the transplant work?
To better understand this approach, imagine the gut microbiota as a forest.
In a balanced ecosystem, different species live side by side, share the available resources and naturally limit the growth of unwanted organisms.
But when an event disrupts this balance, some species can disappear, leaving more room for other microorganisms.
This is what can happen after antibiotic therapy. While antibiotics are essential for treating many bacterial infections, they can also destroy some of the beneficial gut bacteria. This disruption can then encourage the growth of certain pathogenic bacteria.
Fecal microbiota transplantation aims to restore a more functional ecosystem by reintroducing a diverse microbial community. This community can help fill the available ecological niches and restore certain protective interactions.
Several mechanisms contribute to this effect: competition between microorganisms for nutrients, the transformation of bile acids and the production of microbial metabolites.
Unlike conventional probiotics, which usually provide a limited number of selected strains, fecal microbiota transplantation transfers a far more complex microbial community.
Clostridioides difficile: results that changed the game
Fecal microbiota transplantation has achieved its most convincing results in the treatment of recurrent Clostridioides difficile infections.
This bacterium can cause severe diarrhea, abdominal pain and inflammation of the colon, which is sometimes serious. It tends to thrive when the gut microbiota has been weakened by antibiotics.
The difficulty is that, in some patients, the infection comes back despite appropriate antibiotic treatment. Recurrences can then become particularly hard to manage.
In 2013, a clinical trial published in the prestigious New England Journal of Medicine marked a turning point in this field.
The researchers observed very encouraging results: 81% of patients who received fecal microbiota transplantation saw their infection clear after a first administration, compared with 31% in the group that received the comparison antibiotic treatment. After a second administration, the resolution rate reached 94% in the transplant group.
The difference in effectiveness was so large that the trial was stopped early. These results helped move fecal microbiota transplantation from a fringe approach to a genuine treatment option in certain situations.
And today?
The American Gastroenterological Association (AGA) guidelines published in 2024 confirm the value of fecal microbiota–based therapies in preventing recurrent C. difficile infection in certain patients, after appropriate antibiotic treatment.
This recommendation remains conditional, however: the decision depends on each patient's health status, immune profile and clinical situation.
From transplants to capsules: a new generation of treatments
For a long time, fecal microbiota transplantation relied on fairly demanding procedures. Preparations were often administered by colonoscopy or through a feeding tube.
Researchers therefore sought to develop simpler, better-standardized forms that are easier to administer.
A major step forward came in the United States with the approval of two treatments derived from fecal microbiota:
- REBYOTA, approved by the FDA in 2022, is administered rectally.
- VOWST, approved in 2023, comes as capsules taken by mouth.
Both treatments are intended to prevent recurrent C. difficile infection in adults, after antibiotic treatment.
The results of the clinical trial evaluating VOWST are particularly interesting: in the eight weeks after treatment, 12.4% of patients who took the capsules had a new infection, compared with 39.8% in the placebo group.
These advances show the progress made in developing standardized microbial treatments. The therapeutic approach is evolving: it is no longer only about eliminating the bacterium causing the infection, but also about restoring the protective functions of the gut ecosystem.
Crohn's disease, diabetes, obesity… how far can this approach go?
This is undoubtedly one of the most fascinating aspects of microbiota research.
For several years, scientists have been studying its role in many diseases, including outside the digestive system. Studies are exploring the possible use of fecal microbiota transplantation in inflammatory bowel diseases, metabolic disorders and certain neurological conditions.
A 2017 Franceinfo article already discussed these prospects, notably for Crohn's disease, obesity, diabetes and certain neurological disorders.
But nearly ten years later, it is essential to distinguish research leads from truly validated treatments.
The AGA guidelines published in 2024 do not recommend fecal microbiota transplantation as a treatment for Crohn's disease, ulcerative colitis or irritable bowel syndrome outside clinical trials. The results remain too variable or insufficient for it to become standard practice for these conditions.
For metabolic and neurological diseases, research is also ongoing, but it would be premature to consider transplantation a proven treatment.
Changing the microbiota can influence certain biological parameters, but that does not mean a complex disease can be treated simply by replacing gut bacteria.
A strictly regulated medical procedure
Despite its potential, fecal microbiota transplantation is not a trivial procedure.
A donor's microbiota can contain potentially pathogenic microorganisms, even when the donor has no symptoms. The risk of transmitting infectious agents therefore requires strict precautions.
Donors undergo rigorous screening, including medical questionnaires and laboratory tests. Preparations must then meet precise requirements for manufacturing, storage and traceability.
In France, fecal microbiota transplantation is regulated by health authorities and falls under specialized medical care.
It is therefore in no way a technique to perform yourself or outside an appropriate medical setting.
What this discovery teaches us about gut health
Beyond its therapeutic applications, fecal microbiota transplantation teaches us an essential lesson: gut health does not depend only on the presence or absence of a single bacterium, but also on the interactions between the many microorganisms that make up our microbiota.
Microbial diversity, metabolic functions and the ecosystem's ability to withstand disruption all play an important role in its balance.
This understanding echoes some of naturopathy's concerns, especially the importance given to diet and lifestyle habits in maintaining good digestive health.
Dietary fibre, a variety of plant foods and certain fermented foods can help shape the composition and activity of the gut microbiota.
These nutritional approaches should, however, be distinguished from fecal microbiota transplantation. A microbiota-friendly diet helps maintain it, whereas FMT is a specific medical intervention intended for certain medical conditions.
And tomorrow?
Microbiota research could pave the way for even more targeted treatments.
Rather than systematically transferring an entire microbial community, scientists are seeking to identify the species, bacterial combinations or metabolites responsible for the observed therapeutic effects.
The goal would be to develop better-defined, more reproducible microbial treatments tailored to specific diseases.
This shift could gradually transform the way we approach certain conditions. After long seeking to eliminate the bacteria that cause infections, medicine is now learning to harness certain microbial communities to restore essential functions of the body.
And this may be one of the most promising prospects of microbiota research.
Scientific sources
Franceinfo (2017). C'est quoi la « transplantation fécale », cette technique qui nous soignera peut-être tous demain ? Article by Camille Caldini (in French). The original source that served as the starting point for this article.
Van Nood E. et al. (2013). Duodenal infusion of donor feces for recurrent Clostridium difficile. New England Journal of Medicine, 368, 407-415. DOI: 10.1056/NEJMoa1205037.
Peery A. F. et al. (2024). AGA Clinical Practice Guideline on Fecal Microbiota–Based Therapies for Select Gastrointestinal Diseases. Gastroenterology, 166(3), 409-434. DOI: 10.1053/j.gastro.2024.01.008.
U.S. Food and Drug Administration (FDA), 2022-2023. Approvals and clinical data for REBYOTA and VOWST.



































